← All trials
NCT05381428
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- May 19, 2022
- Last posted
- May 19, 2022
- Enrollment
- 1250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ParmaLead sponsor
- University of Modena and Reggio EmiliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.